Description

BSE announces listing of 1500 Commercial Papers worth Rs. 5 lakh each issued by Nuvama Wealth and Investment Limited on private placement basis, effective November 13, 2025.

Summary

BSE has listed 1500 Commercial Papers of Nuvama Wealth and Investment Limited issued on private placement basis, each with face value of Rs. 5,00,000. The securities are admitted to dealings on the BSE Debt segment with effect from November 13, 2025. The instruments are rated CARE A1+ and CRISIL A1+, with ICICI Bank Limited acting as the Issuing and Paying Agent.

Key Points

  • Quantity: 1500 Commercial Papers
  • Face Value: Rs. 5,00,000 per unit
  • Issue Price: Rs. 4,90,702 per unit
  • Scrip Code: 730555
  • Scrip ID: NWIL121125
  • ISIN: INE523L14AQ9
  • Credit Rating: CARE A1+, CRISIL A1+
  • Market Lot: 1 unit
  • Tick Size: 1 paise
  • Trading Mode: Dematerialized form only
  • Standard Denomination: Rs. 5 lakhs and multiples thereof

Regulatory Changes

No regulatory changes introduced. This is a standard listing notification for debt instruments issued on private placement basis.

Compliance Requirements

  • Trading members must trade these securities only in dematerialized form under ISIN INE523L14AQ9
  • Trading shall take place in standard denomination of Rs. 5 lakhs and multiples thereof
  • Tick size of 1 paise must be observed for price movements
  • Queries should be directed to BSE debt department on specified contact numbers: 22728352/8597/8995/5753/8915

Important Dates

  • Allotment Date: November 12, 2025
  • Listing Date: November 13, 2025
  • Redemption Date: February 11, 2026
  • Tenure: 91 days (approximately 3 months)

Impact Assessment

This listing has minimal market impact as it pertains to routine debt instrument listing on the BSE Debt segment. The commercial paper issuance is part of Nuvama Wealth and Investment Limited’s short-term funding requirements. The instruments carry high credit ratings (A1+ from both CARE and CRISIL), indicating low credit risk. Impact is limited to debt market participants and institutional investors dealing in short-term corporate debt instruments. No impact on equity markets or broader trading operations.

Impact Justification

Routine debt instrument listing with no market-wide implications. Affects only debt segment participants trading in Nuvama's commercial paper.